Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers

A meta-analysis

Rongqiang Liu, MD,a,b, Shiyang Zheng, MD,c, Cuī yan Yang, MD,b, Yajie Yu, MD,a, Shengjia Peng, MD,a,
Qianmin Ge, MD,a, Qi Lin, MD,a, Qiuyu Li, MD,a, Wenqing Shi, MD,a, Yi Shao, PhD,a,*

Abstract

Background: Numbers of studies have reported that the expression of aldo-keto reductase family 1 member B10 (AKR1B10) is abnormal in digestive system cancers, and could be used as a prognostic biomarker. However, the results are argued. Therefore, we conduct a meta-analysis to comprehensively evaluate the prognostic value of high AKR1B10 expression for overall survival (OS), disease specific survival (DSS), and disease-free survival/recurrence-free survival (DFS/PFS) in digestive system cancers.

Methods: Hazard ratios (HRs) with its 95% confidence intervals (CIs) were calculated to assess the prognostic value of AKR1B10 by using the random effects model. The STATA version 12.0 software were used to perform all the analyses.

Results: Eleven articles including 1428 patients involved in this meta-analysis. The pooled analysis suggested that high AKR1B10 expression was not associated with OS (HR: 1.18; 95% CI: 0.69–2.00) and DFS/PFS (HR: 1.08, 95% CI: 0.67–1.76) in digestive system cancers. However, Further analysis revealed that high AKR1B10 expression indicated poor OS in oral squamous cell carcinomas (OSCC) (HR: 2.92, 95% CI: 1.86–4.58) and favorable DSS in hepatocellular carcinoma (HCC) (HR: 0.71, 95% CI: 0.52–0.97).

Conclusions: The prognostic value of high AKR1B10 expression varied in different types of digestive system cancers. Further studies exploring the prognostic role of AKR1B10 in digestive system cancers are needed.

Abbreviations: AKR1B10 = aldo-keto reductase family 1 member B10, CI = confidence interval, CRC = colorectal cancer, DFS/PFS = disease-free survival/recurrence-free survival, DSS = disease specific survival, GC = gastric cancer, HCC = hepatocellular carcinoma, HR = hazard ratio, NOS = Newcastle-Ottawa Quality Assessment Scale, OS = overall survival, OSCC = oral squamous cell carcinomas.

Keywords: aldo-keto reductase family 1 member B10, digestive system cancers, meta-analysis, prognosis

1. Introduction

The aldosterone reductase family is a small class of monomer-soluble proteins that perform redox reactions with nicotinamide adenine dinucleotide phosphate as a coenzyme. It plays an indispensable role in the detoxification, metabolism, and lipid synthesis of the human body, as well as the complications of diabetes.[1,2] It also has an important effect on tumorigenesis, and can be severed as useful biomarkers for tumor diagnosis and
prognosis. The location of AKR1B10 gene is on chromosome 7q33, and the AKR1B10 protein is composed of 316 amino acids. AKR1B10 is involved in various pathophysiological activities of the body, such as detoxification, retinoic acid metabolism, and lipid synthesis. Studies have shown that AKR1B10 is characterized by obvious carcinogenicity and can be used as a tumor marker. Recently, an increasing number of studies have explored the association between AKR1B10 expression and prognostic value in digestive system cancers. For example, Yao et al. confirmed that low AKR1B10 expression indicated poor prognosis for gastric cancer (GC) and colorectal cancer (CRC). Wang et al. also found that high AKR1B10 expression revealed a lower risk of recurrence in patients with hepatocellular carcinoma (HCC). However, Fang et al. demonstrated that AKR1B10 was significantly correlated with tumor size, perineural invasion and recurrence, and was a risk factor for poor prognosis in oral squamous cell carcinomas (OSCC). Jin et al. also showed that high AKR1B10 expression was related to a shorter disease free survival (DFS) and overall survival (OS). The conclusions of the above researches are controversial. The prognostic significance of AKR1B10 in digestive system cancers remains unclear. Therefore, we implemented a meta-analysis to further evaluate the prognostic role of AKR1B10 in digestive system cancers. In addition, we also discussed the suitability of AKR1B10 as a prognostic marker for cancers.

2. Material and methods

2.1. Search strategy

We synthetically searched the literature available on PubMed, EMBASE, and Web of Science until August 31, 2020. The following key words were used: “AKR1B10” OR “aldo-keto reductase family 1 member B10” OR “Aldo-keto reductase 1B10” AND “cancer” OR “canceroma” OR “neoplasm” OR “tumor” OR “tumor” AND “prognosis” OR “prognostic” OR “survival” OR “outcome”. We earnestly screened the titles, abstracts, full texts, and reference lists to select objective studies. Two authors (RQ.L and CY.Y) independently performed the search. This study does not require the approval of the ethics committee because it is a meta-analysis.

2.2. Selection criteria

The inclusion criteria were listed:
1. investigated patients with digestive system cancers;
2. determined the expression of AKR1B10 in blood or tumor tissue;
3. explored the relationship between the expression level of AKR1B10 and survival outcome; and
4. provided ample data to compute the hazard ratio (HR) and its 95% confidence interval (CI).

The exclusion criteria were listed:
1. provided insufficient data to calculate the HR and 95% CI;
2. case reports, abstracts, reviews, letters and non-English language publications;
3. animal or cell experiments; and
4. data from public databases.

2.3. Data extraction and quality assessment

Basic information was independently collected by 2 authors (RQ.L and CY.Y). The relevant information were listed including the first author name, publication year, country, study type, tumor type, sample size, detected method, analysis type and HRs with the corresponding 95% CIs. Multivariate analysis which considered the confounding factors and exhibited high accuracy was preferred. The HR value was extracted by Kaplan–Meier curves. The Newcastle–Ottawa Quality Assessment Scale (NOS) was used to evaluate the quality of each included study.

2.4. Statistical analysis

HRs and the corresponding 95% CIs were applied to calculated comprehensive results. We directly used statistical variables in our analysis if they were displayed in the study. Otherwise, we adopted the methods described by Tierney to extract the data from graphical survival plots. A fixed effects model was applied to synthesized HRs when \( I^2 \) was <50%; Otherwise, a random effects model was used. The sources of heterogeneity were by subgroup and regression analysis. Publication bias was investigated by Begg test and Egger test. All the analyses were performed by the STATA version 12.0 software (Stata Corporation, College Station, TX, USA). P values <.05 denoted statistically differences.

3. Results

3.1. Study selection

Three hundred fifty seven articles were initially collected from specified database. After removing 134 duplicates, 223 articles were screened for further information. Two hundred two articles were excluded according to the title and abstracts, and 21 articles were further evaluated. After full-text review, thirteen articles were excluded. Eventually, we identified eleven articles published between 2014 and 2020. The flow diagram of the selection is displayed in Figure 1.

3.2. Study characteristics

The included articles involved a total of 1428 patients, ranging from 53 to 255. In all studies, the expression of AKR1B10 was detected in tumor tissue. Eight studies detected the AKR1B10 by immunohistochemistry and 3 studies by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Ten studies were conducted in Asian and one in Caucasian. Four different cancers were assessed, including OSCC, GC, HCC, and CRC. Ten HRs were reported in the included studies and 1 HRs was further evaluated. After full-text review, thirteen articles were excluded. Eventually, we identified eleven articles published between 2014 and 2020. The flow diagram of the selection is displayed in Figure 1.

3.3. Association of AKR1B10 expression with OS

Nine studies focused on OS analysis. Due to the apparent heterogeneity \( I^2 = 88.9\% \), the random effects model was applied. The pooled results displayed that high AKR1B10 expression was not associated with OS in digestive system cancers (HR: 1.18, 95% CI: 0.60–2.32) (Fig. 2).
3.4. Subgroup analysis

Subgroup analyses were implemented based on the cancer type, analysis type, country, detected methods, NOS score (Table 2). We found that high AKR1B10 expression displayed no correction with OS in HCC (HR: 1.01, 95% CI: 0.38–2.69) and GC (HR: 1.40, 95% CI: 0.13–14.99). However, high AKR1B10 expression indicated obvious worse OS in OSCC (HR: 2.92, 95% CI: 1.86–4.58). Furthermore, in the subgroup NOS = 6, we noticed high AKR1B10 expression suggested unfavourable OS (HR: 2.60, 95% CI: 1.80–3.76). All other subgroups containing more than 2 studies revealed that there were no significant association between elevated AKR1B10 expression and OS. In addition, we also used GEPIA Database to assess the prognostic role of AKR1B10 in a single tumor. We found that high AKR1B10 expression was associated with unfavorable OS in HCC, but not in GC and CRC (Fig. 3).

3.5. Association of AKR1B10 expression with DFS/RFS, DSS

Six studies that reported DFS/RFS showed obvious heterogeneity ($I^2 = 80.2\%$). A random effects model was conducted to

---

Table 1

| Study | Year | Country | Study type  | Tumor type | Sample size | Detected sample | Detected method | Analysis type | Survival analysis | Source of HR | NOS score |
|-------|------|---------|-------------|------------|-------------|----------------|----------------|--------------|------------------|-------------|-----------|
| Jin   | 2016 | China   | Retrospective | HCC | 144      | Tissue | qPCR | Multivariate | OS, DFS | Reported | 6         |
| Fang  | 2019 | China   | Retrospective | OSCC | 107      | Tissue | IHC | Multivariate | OS, DFS | Reported | 7         |
| Ko    | 2017 | China   | Retrospective | OSCC | 77       | Tissue | IHC | Multivariate | OS | Reported | 6         |
| Schmitz | 2011 | Germany | Retrospective | HCC | 168      | Tissue | IHC | Univariate | OS | Reported | 7         |
| Sonohara | 2016 | Japan   | Retrospective | HCC | 158      | Tissue | qPCR | Multivariate | OS, RFS | Reported | 7         |
| Liu   | 2015 | China   | Retrospective | HCC | 109      | Tissue | IHC | Multivariate | OS, RFS | Reported | 7         |
| Wang  | 2017 | China   | Retrospective | HCC | 110      | Tissue | IHC | Multivariate | OS, RFS | Reported | 7         |
| Yao   | 2014 | China   | Retrospective | GC  | 112      | Tissue | IHC | Univariate | OS | Reported | 7         |
| Ha    | 2014 | China   | Retrospective | HCC | 255      | Tissue | IHC | Multivariate | DSS, DFS | Reported | 7         |
| Ahmed | 2020 | Korea   | Retrospective | GC  | 53       | Tissue | IHC | Multivariate | OS | Reported | 6         |
| Yao   | 2020 | China   | Retrospective | CRC | 135      | Tissue | qPCR | Multivariate | OS | Reported | 7         |

CRC = colorectal cancer, DFS = disease-free survival, DSS = disease specific survival, GC = gastric cancer, HCC = hepatocellular carcinoma, OS = overall survival, OSCC = oral squamous cell carcinomas, RFS = recurrence-free survival.
Figure 2. Forest plot of association of high AKR1B10 expression with OS.

Table 2
Subgroup analysis for OS in patients with high AKR1B10 expression.

| Stratified analysis          | No. of studies | HR (95% CI)   | P value | Heterogeneity | F (%) | P value | Model |
|------------------------------|----------------|---------------|---------|---------------|-------|---------|-------|
| **Cancer type**              |                |               |         |               |       |         |       |
| HCC                          | 4              | 1.01 (0.38–2.69) | .982    | 88.3          |       |         | Random |
| OSCC                         | 2              | 2.92 (1.86–4.58) | .294    | .232          | 88.3  |         | Fixed  |
| GC                           | 2              | 1.40 (0.13–14.99) | .782    | 88.3          |       | .004    | Random |
| CRC                          | 1              | 0.40 (0.24–0.67) |         |               |       |         |       |
| **Analysis type**            |                |               |         |               |       |         |       |
| Univariate analysis          | 1              | 0.46 (0.25–0.87) |         |               |       |         |       |
| Multivariate analysis        | 8              | 1.34 (0.65–2.75) | .425    | 88.9          |       |         | Random |
| **Country**                  |                |               |         |               |       |         |       |
| China                        | 7              | 0.00 (0.43–1.86) | .768    | 89.6          |       |         | Random |
| Japan                        | 1              | 3.06 (1.58–5.71) |         |               |       |         |       |
| Korea                        | 1              | 5.23 (1.13–24.13) |        |               |       |         |       |
| **Detected method**          |                |               |         |               |       |         |       |
| IHC                          | 6              | 1.13 (0.45–2.83) | .794    | 88.5          |       |         | Random |
| qPCR                         | 3              | 1.30 (0.39–4.34) | .664    | 93            |       |         | Random |
| **NOS score**                |                |               |         |               |       |         |       |
| NOS = 6                      | 3              | 2.60 (1.80–3.76) | .47     | .15           |       |         | Fixed  |
| NOS = 7                      | 6              | 0.76 (0.35–1.63) | .873    | .48           |       |         | Random |
perform the pooled HR. Comprehensive analysis revealed that there was no significant relationship between high AKR1B10 expression and DFS/RFS (HR: 1.08, 95% CI: 0.67–1.76) (Fig. 4). DFS and RFS also were used to analyze the data. The results indicated that high AKR1B10 expression was not connected with DFS (HR: 1.43; 95% CI: 0.61–3.33) and RFS (HR: 0.82; 95% CI: 0.45–1.50). In addition, 2 studies about HCC reported DSS. The results suggested that high AKR1B10 expression displayed the favorable DSS (HR: 0.71, 95% CI: 0.52–0.97) (Fig. 5).

3.6. Sensitivity analysis
Sensitivity analysis was displayed by sequentially omitting 1 study in turn. The results were not significantly changed from the above results, suggesting that the outcomes were robust for OS (Fig. 6A) and DFS/PFS (Fig. 6B).

3.7. Publication bias
The publication bias for the total OS or DFS/RFS analyses were performed by funnel plots. Begg test and Egger test were applied to display the statistical evidence of funnel plot symmetry. P values of Begg test and Egger test were 1.00 and 0.856 for OS (Fig. 7A) and 0.260 and 0.267 for DFS/RFS (Fig. 7B), respectively. No significant publication bias was observed.

4. Discussion
This study was the first meta-analysis to comprehensively assess the prognostic role of AKR1B10 in digestive system cancers.
Eleven studies involving 1428 patients were included. Nine studies assessed OS data, 6 studies evaluated DFS/RFS data and 2 studies about HCC reported the DSS data. The results demonstrated that high AKR1B10 expression was not correlated with worse OS (HR: 1.18; 95% CI: 0.60–2.32) and DFS/RFS (HR: 1.08, 95% CI: 0.67–1.76) in digestive system cancers. However, there was obvious association between high AKR1B10 expression and DSS (HR: 0.71, 95% CI: 0.52–0.97) in HCC. Based on subgroup analysis, we found that high AKR1B10 expression indicated worse OS in OSCC, but not in HCC and GC. Shi et al., showed that high AKR1B10 expression indicated poor OS in HCC patients according to the TCGA database. This is consistent with our database analysis based on TCGA, but different from our meta-analysis. We speculated that this was due to the fact that we included fewer literatures about HCC, while the TCGA database had abundant data resources. In addition, it may be caused by the differences in research methods, statistical methods, detection methods, sample sizes and the clinical experience of researchers in the included literatures.

AKR1B10 regulates tumors through various mechanisms. Ohashi et al, found that low AKR1B10 expression could inhibit p53-induced apoptosis of colorectal cancer cells and promote tumor development. In lung cancer, AKR1B10 may regulate the proliferation, adhesion, and invasion of cancer cells via ERK/MAPK signaling pathway. In breast cancer, AKR1B10 could enhance the invasion and metastasis of cancer by regulating the extracellular signal regulated kinase (ERK) and FAK/Src/Rac1 signaling pathways. Wang et al, revealed that deletion or inhibition of the AKR1B10 gene affected mitochondrial function and induced oxidative stress to promote apoptosis of tumor cells. Moreover, silencing the expression of AKR1B10 could inhibit the proliferation, invasion and metastasis of pancreatic cancer cells by modulating the Kras-E-cadherin pathway. Sphingosine-1-phosphate (S1P) is a bioactive phospholipid and closely related to tumor progression. Jin et al, reported that AKR1B10 promoted the proliferation of liver cancer cells by increasing the secretion of S1P. Furthermore, epidermal growth factor induced tumor marker AKR1B10 expression through activator protein-1 signaling to promote the proliferation of liver cancer cells. The mechanism involved in the regulation of tumors by AKR1B10 is complex and warrants further investigation.

This study was characterized by several limitations. Firstly, all included studies had small sample sizes, which increased the likelihood of inaccurate results. Secondly, there was significant
heterogeneity and the results needed to be treated with caution. Thirdly, the research methods of different studies and cut-off values were inconsistent, which may affect the evaluation of AKR1B10 as a prognostic biomarker. Fourthly, most studies involved in the study were implemented in Asia. Finally, we did not investigate the relationship between AKR1B10 and other pathological parameters due to insufficient data, such as tumor stage and metastasis.

Figure 5. Forest plot of association of high AKR1B10 expression with DSS in HCC.

Figure 6. Sensitivity analysis. (A) Sensitivity analysis for OS. (B) Sensitivity analysis for DFS/PFS.
In conclusion, we demonstrated that the prognostic value of high AKR1B10 expression varied in different types of digestive system cancers. Further studies exploring the prognostic role of AKR1B10 in digestive system cancers are needed.

Author contributions

Data curation: Rongqiang Liu, Shiyang Zheng, Cui yan Yang.
Formal analysis: Rongqiang Liu, Shiyang Zheng, Cui yan Yang.
Funding acquisition: Yi Shao.
Investigation: Rongqiang Liu, Shiyang Zheng, Cui yan Yang.
Methodology: Rongqiang Liu, Shiyang Zheng, Cui yan Yang.
Project administration: Yi Shao.
Resources: Rongqiang Liu.
Software: Rongqiang Liu, Shiyang Zheng, Cui yan Yang.
Supervision: Yajie Yu, Shengjia Peng, Qianmin Ge, Qi Lin, Qiuyu Li, Wenqing Shi.
Writing – original draft: Rongqiang Liu.
Writing – review & editing: Rongqiang Liu, Yi Shao.

References

[1] Barski OA, Tipparaju SM, Bhattacharyya A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008;40:533–624.
[2] Chen WD, Zhang Y. Regulation of aldo-keto reductases in human diseases. Front Pharmacol 2012;3:33.
[3] Penning TM. The aldo-keto reductases (AKRs): Overview. Chem Biol Interact 2015;234:236–46.
[4] Huang L, He R, Luo W, et al. Aldo-keto reductase family 1 member B10 inhibitors: potential drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2016;11:184–96.
[5] Fang CY, Lin YH, Chen CL. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients. J Oral Pathol Med 2019;48:712–9.
[6] Ko HH, Cheng SL. Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma. Head Neck 2017;39:1327–32.
[7] Ha SY, Song DH, Lee JJ, et al. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma. Gut Liver 2014;8:48–54.
[8] Schmitz KJ, Sotropoulos GC, Baba HA, et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int 2011;31:810–6.
[9] Sonohara F, Inokawa Y, Hishida M, et al. Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncol Lett 2016;12:4821–8.
[10] Jin J, Liao W, Yao W, et al. Aldo-keto reductase family 1 member B10 mediates liver cancer cell proliferation through Sphingosine-1-Phosphate. Sci Rep 2016;6:22746.
[11] Ahmed SMU, Jiang ZN, Zheng ZH, et al. AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett 2019;17:773–80.
[12] Liu TA, Jan YJ, Ko BS, et al. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3epsilon and their prognostic impact of hepatocellular carcinoma. Oncotarget 2015;6:38967–82.
[13] Wang YJ, Qi LN, Zhong JH, et al. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2017;7:42199.
[14] Yao HB, Xu Y, Chen LG, et al. AKR1B10, a good prognostic indicator in gastric cancer. Eur J Surg Oncol 2014;40:318–24.
[15] Yao Y, Wang X, Zhou D, et al. Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging (Albany NY) 2020;12:13059–75.
[16] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[17] Tierney JF, Stewart LA, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
[18] Ohashi T, Idogawa M, Sasaki Y, et al. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res 2013;11:1554–63.
[19] Zhou Z, Zhao Y, Gu L, et al. Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. Mol Med Rep 2018;17:2153–60.
[20] Huang C, Verhulst S, Shen Y, et al. AKR1B10 promotes breast cancer cell metastasis through integrin alpha5delta-catenin mediated FAKSrc/Rac1 signaling pathway. Oncotarget 2016;7:43779–91.
[21] Li J, Guo Y, Duan L, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget 2017;8:31694–703.
[22] Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009;284:26742–8.

[23] Zhang W, Li H, Yang Y, et al. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway. Cancer Lett 2014;355:273–80.

[24] Pyne NJ, Tonelli F, Lim KG, et al. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012;40:94–100.

[25] Liu Z, Yan R, Al-Salman A, et al. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. Biochem J 2012;442:273–82.

[26] Shi J, Chen L, Chen Y, et al. Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma. J Cancer 2019;10:4892–901.